Medical Segment Dominates, Expected to Reach $70.4 Billion by 2030 in the Global Recombinant DNA Technology Market

DUBLIN, Oct. 31, 2023 /PRNewswire/ — The “Recombinant DNA Technology: Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

The global market for Recombinant DNA Technology estimated at US$64.7 Billion in the year 2022, is projected to reach a revised size of US$93.7 Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2022-2030.

Medical, one of the segments analyzed in the report, is projected to record 5.2% CAGR and reach US$70.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Non-Medical segment is readjusted to a revised 3.4% CAGR for the next 8-year period.

The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 4.4% CAGR

The Recombinant DNA Technology market in the U.S. is estimated at US$18.9 Billion in the year 2022. China, the world’s second largest economy, is forecast to reach a projected market size of US$16.5 Billion by the year 2030 trailing a CAGR of 4.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.2% and 3.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Select Competitors (Total 32 Featured) –

Amgen IncBamboo Therapeutics, Inc.BioconBiogenChiron CorporationCibusEli Lilly and CompanyF. Hoffmann-La Roche LtdGenentech, IncGenScriptGlaxoSmithKline plc.Horizon Discovery Group plcMerck KGaAMonsanto CompanyNew England BiolabsNovartis AGNovo Nordisk A/SNucelisPfizer Inc.ProfacgenSanofiSyngene

What’s New?

Special coverage on Russia–Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.Global competitiveness and key competitor percentage market sharesMarket presence across multiple geographies – Strong/Active/Niche/TrivialOnline interactive peer-to-peer collaborative bespoke updatesAccess to digital archives and Research PlatformComplimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market InsightsWorld Market TrajectoriesImpact of Covid-19 and a Looming Global RecessionRecombinant DNA Technology – Global Key Competitors Percentage Market Share in 2022 (E)Competitive Market Presence – Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/lpiytc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
 

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

 

 

View original content:https://www.prnewswire.com/news-releases/medical-segment-dominates-expected-to-reach-70-4-billion-by-2030-in-the-global-recombinant-dna-technology-market-301972647.html

SOURCE Research and Markets